Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Transgene Biotek has informed BSE that Regulation 57 of the SEBI Listing Obligations and Disclosure Requirements is not applicable to the company for the quarter ended December 31, 2025. The regulation requires disclosure of interest, dividend, or principal payments on non-convertible securities, and the company states it has no such non-convertible securities outstanding during the quarter. The communication was signed by Dr K Koteswara Rao, Chairman and Managing Director.
This is a routine nil-compliance confirmation with no impact on shareholders or stock price, as the company simply has no non-convertible debt instruments requiring periodic disclosure.